Skip to content

Validation of a new method by nano-liquid chromatography on chip tandem mass spectrometry for combined quantitation of C3f and the V65 vitronectin fragment as biomarkers of diagnosis and severity of osteoarthritis

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)170-180
Number of pages11
JournalTalanta
Volume169
Early online date28 Mar 2017
DOIs
DateAccepted/In press - 25 Mar 2017
DateE-pub ahead of print - 28 Mar 2017
DatePublished (current) - 1 Jul 2017

Abstract

Microfluidic liquid chromatography coupled to a nanoelectrospray source ion trap mass spectrometry was used for the absolute and simultaneous quantitation of C3f and the V65 vitronectin fragment in serum. The method was first carefully optimized and then validated in serum biological matrix. Stable isotopes for the two biomarkers of interest were used as stable isotope labeled peptide standards. A weighted 1/x2 quadratic regression for C3f and a weighted 1/x quadratic regression for the V65 vitronectin peptide were selected for calibration curves. Trueness (with a relative bias <10%), precision (repeatability and intermediate precision <15%) and accuracy (risk <15%) of the method were successfully demonstrated. The linearity of results was validated in the concentration range of 2.5–200 ng/mL for C3f and 2.5–100 ng/mL for the V65 vitronectin fragment. Serum samples (n=147) classified in 7 groups [(healthy volunteers, OA with 5 grades of severity and rheumatoid arthritis (RA) patients] were analyzed with our new quantitative method. Our data confirm that C3f and the V65 vitronectin fragment are biomarkers of OA severity, but also that C3f fragment is further related to OA severity whereas the V65 vitronectin fragment is more related to early OA detection.

    Research areas

  • liquid chromatography-chip, mass spectrometry, peptide quantitation, complement C3, vitronectin, validation, serum

Documents

View research connections

Related faculties, schools or groups